
Adult hippocampal dentate gyrus (DG) neurogenesis declines with brain ageing, contributing to cognitive impairment. Catalpol, an iridoid glycoside from Rehmannia glutinosa, exerts robust neuroprotective effects, yet its poor brain penetration (XLogP3-AA ≈ -3.2; TPSA = 162Ų) poses a pharmacokinetic paradox. We propose the Catalpol-Gut-Brain-Neurogenesis Axis (CGBNA) as a falsifiable framework generating four predictions: (i) germ-free or microbiota-depleted animals will not exhibit catalpol-induced DG neurogenesis or cognitive improvement; (ii) hippocampal tissue will contain gut-derived phenolic metabolites, not intact catalpol, at functionally relevant concentrations after oral catalpol; (iii) re-colonisation with catalpol-metabolising bacteria will restore these effects; (iv) direct administration of candidate metabolites will recapitulate catalpol's neurogenic and cognitive effects. Direct in vivo evidence that orally administered isolated catalpol is converted by gut microbiota into scopoletin, protocatechuic acid, or vanillic acid at functionally relevant concentrations remains lacking. These predictions define the experimental agenda for validating or refuting the CGBNA.
Prenatal valproic acid (VPA) exposure is widely used to model autism spectrum disorder (ASD), yet the persistence of its behavioral effects and the accompanying multilevel neurobiological abnormalities remain incompletely understood. Here, we integrated behavioral, histological, morphological, electrophysiological, molecular, metabolomic, and epigenomic analyses to characterize the long-term effects of prenatal VPA exposure in rats from early postnatal life through adulthood. Prenatal VPA exposure caused delayed early development and persistent ASD-like phenotypes, including repetitive behaviors, impaired social interaction, anxiety-like behavior, reduced exploration, and cognitive deficits. These behavioral abnormalities were accompanied by neuronal and glial alterations and reduced dendritic complexity and spine density in the medial prefrontal cortex and hippocampus, as well as reduced excitatory and inhibitory synaptic inputs and decreased expression of key synaptic proteins in the medial prefrontal cortex. Multi-omics profiling further identified candidate metabolic alterations involving membrane lipid remodeling, neuromodulatory metabolism, and inflammatory lipid signaling, alongside bidirectional, locus-specific DNA methylation changes enriched in neurodevelopmental and synaptic pathways. Together, these findings show that prenatal VPA exposure produces persistent ASD-like phenotypes accompanied by multilevel cellular, structural, synaptic, metabolic, and epigenetic abnormalities. This work provides an integrated framework for understanding the long-term consequences of prenatal VPA exposure and supports the VPA model as a valuable platform for investigating mechanisms underlying ASD.
Rats and mice are widely studied to inform human diseases. However, there are important biological differences between humans and rodents. For example, humans progress through development and aging much more slowly than rodents. The compressed timescale of rodent development and aging creates challenges to translate findings from rodents to humans. We draw insights from the Translating Time research project, which is a long-term project that integrates thousands of biological and behavioral measures to establish age equivalences across different species. We discuss how to align ages between humans and mice and rats in the context of developmental (e.g., spinal muscular atrophy, autism) and age-related disorders (e.g., Alzheimer's disease). Age is an important factor to consider in the selection of a model. For example, assuming age-related dementia rates are similar in humans and mice, few mice live to develop dementia once their ages are merged onto a common template. Examples such as these show that mice models are well suited for some diseases but may be limited to study others, especially for those that occur a geriatric stages of life. Finally, we discuss how a One Health approach can complement laboratory research to advance biomedicine.
Depression is a prevalent psychiatric disorder characterized by significant social and individual burden. Hippocampal calcium overload and glutamate excitotoxicity are key pathological features, with excitatory amino acid transporter 2 (EAAT2) playing a pivotal role in glutamate clearance. Emerging evidence implicates endoplasmic reticulum stress and its downstream mediator X-box binding protein 1 (XBP-1) in neuronal dysfunction; however, their interaction in depression remains unclear. Here, a corticosterone (CORT)-induced mouse model of depression and a primary hippocampal neuron model were employed to investigate the relationship between XBP-1 and EAAT2. Depressive-like behaviors, neuronal injury, and synaptic and mitochondrial alterations were assessed using behavioral assays, histological and ultrastructural analyses, and functional recordings. CORT exposure was associated with increased hippocampal XBP-1s expression, reduced EAAT2 expression, and elevated glutamate content in hippocampal tissue homogenates. In CORT-treated primary hippocampal neurons, XBP-1 knockdown restored EAAT2 expression and reduced extracellular glutamate accumulation and oxidative stress. In mice, Toyocamycin treatment partially improved depressive-like behaviors and attenuated hippocampal neuronal injury, accompanied by reduced XBP-1s and increased EAAT2 protein levels. These findings support a functional relationship between XBP-1 signaling and EAAT2 expression in the experimental models studied. Whether EAAT2 mediates the protective effects of XBP-1 suppression remains to be established.
Epilepsy is a serious neurological condition characterized by spontaneous recurrent seizures affecting approximately 83 million people worldwide. Type 2 diabetes (T2D) and obesity are highly prevalent in persons with epilepsy, significantly influencing long-term outcomes, quality of life, and mortality. Traditionally, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are used to treat T2D and obesity, and they have recently been highlighted as a therapeutic intervention for neurological disorders, including epilepsy. In epilepsy, adenosine signaling plays a crucial role, as it not only controls seizures but also affects epileptogenesis. As a metabolite and metabolic regulator adenosine is also implicated in the pathophysiology of T2D and obesity. The involvement of adenosine in both conditions raises the possibility of convergent mechanisms implicated in the antiepileptic effects of GLP-1 RAs. This review provides a comprehensive overview of the effects of GLP-1 RAs and adenosine in epilepsy and their convergent mechanisms, which could serve as a basis for synergistic therapeutic applications and insight into their underlying mechanisms. GLP-1 RAs affect several mechanisms shared with adenosine signaling. These include reduction of astrogliosis, neuroinflammation, and mTOR activity, and restoration of the excitation and inhibition balance by suppressing the glutamatergic pathway and upregulating the GABAergic pathway. In peripheral organs, direct convergent mechanisms between adenosine signaling and GLP-1 RAs include interactions between adenosine deaminase and dipeptidylpeptidase-4, lipid metabolism, and pancreatic β-cell homeostasis. These convergent mechanisms highlight the need to further investigate possible bidirectional relationships with the involvement of adenosine in both conditions.